Tinnitus. Tinnitus
Conditions
Interventions
Intervention 1: Treatment Group with Acamprosate: taking 666mg/every 8 hr for a month ( if patient's weight is less than 60 kg, total dose will be half= 333mg/every 8 hr). Intervention 2: treatment gr
Treatment - Drugs
Treatment Group with Acamprosate: taking 666mg/every 8 hr for a month ( if patient's weight is less than 60 kg, total dose will be half= 333mg/every 8 hr)
treatment group with placebo: taking 2 peals/ every 8hr for one month( if patient is less than 60 kg, total dose will be half=one peal/every 8hr)
Sponsors
Iran National Science Foundation
ENT, Head and Neck Surgery Research Center
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: inclusion criteria: Normal hearing or mild sensory-neural hearing loss and chronic idiopathic tinnitus(more than 3 months ); age between 18 to 65 years/old. exclusion criteria: recent(less than a month) tinnitus treatment including sound or medical therapy; severe co-morbidities like renal, liver or cardiac diseases; malignancies; past history of treatment-required depression; previous ear surgery; alcohol user; opium or narcotic drugs abuser; pregnant women, lactation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The measure of change in tinitus handicapp inventory. Timepoint: at the end of one month treatment. Method of measurement: audiometry, OAE, VAS, loudness match. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Mahdi Salem
ENT, Head and Neck Surgery Research Center
Outcome results
None listed